2 recruiting, 1 active not recruiting, 1 completed, 1 suspended. 3 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Recruiting 2, Suspended 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow RAD51C Gene Mutation: new trials by email Literature Review of RAD51C Gene Mutation trials Research Report on RAD51C Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion Tamoxifen 10 mg Tablet, Intermittent caloric restriction, Step counter Device - BRCA Mutation, PALB2 Gene Mutation | Phase 2 | Completed | European Institute of Oncology | 110 | 2024-06-21 | 2026-09-11 |
| An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care - BRCA1 Mutation, POLD1 Gene Mutation | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2022-12-01 | 2026-08-27 |
| TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Not applicable | Recruiting | University Medical Center Nijmegen | 3000 | 2020-03-01 | 2026-04-06 |
| Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy - ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Terminated | University of California, Davis | 11 | 2020-02-25 | 2026-05-14 |
| Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome CASCADE genetic screening - BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation | Active not recruiting | NYU Langone Health | 118 | 2019-03-01 | 2026-05-14 | |
| Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) Educational Intervention, Genetic Counseling, Laboratory Biomarker Analysis - BARD1 Gene Mutation, BRCA1 Gene Mutation | Not applicable | Suspended | M.D. Anderson Cancer Center | 5200 | 2017-04-18 | 2026-08-26 |
Breast Carcinoma In Situ (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (4) · Neoplasms by Site (4) · Breast Diseases (2) · Breast Neoplasms (2) · Genital Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Carcinoma (1) · Carcinoma in Situ (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Early Intervention, Educational (1) · Educational Status (1) · Genetic Counseling (1) · Methods (1) · Standard of Care (1) · Tablets (1) · Tamoxifen (1) · niraparib (1)
European Institute of Oncology (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · NYU Langone Health (1) · University Medical Center Nijmegen (1) · University of California, Davis (1)
United States (5) · Italy (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Germany (1) · Ireland (1) · Mexico (1) · Netherlands (1) · Norway (1) · Poland (1) · Spain (1) · Sweden (1)
Bernardo Bonanni, MD (1) · Bhavana Pothuri, MD (1) · Elizabeth M. Swisher, MD, PhD (1) · Joanne A. de Hullu, MD, PhD (1) · Karen H. Lu, MD, PhD (1) · Kenneth Offit, MD, MPH (1) · Marc Dall'Era (1) · Roni Wilke (1)
PMID 31266460, PMID 36155347, PMID 36710203, PMID 37045546, PMID 37707822, PMID 39226292, PMID 39509704
2023 (1), P30CA093373 (1)